文章摘要

参考文献/References

［1］ Cohen M. The role of lowmolecularweight heparin in the management of acute coronary syndromes［J］. J Am Coll Cardiol, 2003,41(4 suppl s):55S-61S.

［2］ Wong GC, Giugliano RP, Antman EM. Use of lowmolecularweight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention［J］. JAMA, 2003,289⑶:331-342.

［3］尤健,曾智.低分子肝素对血管内皮细胞舒缩功能的影响［J］.心脏杂志，2004，16（4）：295-330.

［4］刘兆英,魏延津.低分子量肝素对高龄不稳定型心绞痛患者凝血、纤溶和抗凝指标的影响［J］.心脏杂志，2004，16（2）：146－148.

［5］ Michalis LK, Katsouras CS, Papamichael N,et al. Enoxaparin versus tinzaparin in nonSTsegment elevation acute coronary syndromes: the EVET trial［J］. Am Heart J , 2003,146（2）:304-310.

［6］ Katsouras C, Michalis LK, Papamichael N, et al. Enoxaparin versus tinzaparin in nonSTsegment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months［J］.Am Heart J , 2005,150（3）:385-391.

［7］ Goodman SG, Fitchett D, Armstrong PW,et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in highrisk patients with nonSTsegment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide［J］.Circulation, 2003,107(2):238-244.

［8］ Fitchett DH, Langer A, Armstrong PW,et al. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in highrisk patients with nonSTsegment elevationacute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Longterm results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial［J］.Am Heart J, 2006,151(2):373-379.

［9］ Blazing MA, de Lemos JA, White HD,et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with nonSTsegment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial［J］.JAMA, 2004,292(1):55-64.

［10］ Ferguson JJ, Califf RM, Antman EM,et al. Enoxaparin vs unfractionated heparin in highrisk patients with nonSTsegment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial［J］.JAMA, 2004,292(1):45-54.

［11］Petersen JL, Mahaffey KW, Hasselblad V,et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in nonSTSegment elevation acute coronary syndromes: a systematic overview［J］.JAMA, 2004,292(1):89-96.

［12］Cohen M, Gensini GF, Maritz F,et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute STsegment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial［J］.J Am Coll Cardiol, 2003,42(8):1348-1356.

［13］Wallentin L, Goldstein P, Armstrong PW,et al. Efficacy and safety of tenecteplase in combination with the lowmolecularweight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)3 PLUS randomized trial in acute myocardial infarction［J］.Circulation, 2003,108(2):135-142.

［14］Antman EM, Morrow DA, McCabe CH,et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for STelevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction TreatmentThrombolysis In Myocardial Infarction study 25 (ExTRACTTIMI 25) ［J］.Am Heart J, 2005,149(2) :217-226.

［15］Eikelboom JW, Quinlan DJ, Mehta SR,et al. Unfractionated and lowmolecularweight heparinas adjuncts to thrombolysis in aspirintreated patients with STelevation acute myocardial infarction: a metaanalysis of the randomized trials［J］.Circulation, 2005,112(25):3855-3867.

［16］Martin JL, Fry ET, Sanderink GJ,et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study［J］. Catheter Cardiovasc Interv, 2004,61(2):163-170.

［17］Bhatt DL, Lee BI, Casterella PJ,et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study［J］.J Am Coll Cardiol, 2003,41(1):20-25.

我们的网站为什么显示成这样？

低分子肝素在急性冠脉综合征和冠心病介入治疗中的应用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics